Related Experiment Video

Updated: Mar 24, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Weiping Zou1, Jedd D Wolchok2, Lieping Chen3

  • 1Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA. wzou@med.umich.edu wolchokj@mskcc.org lieping.chen@yale.edu.

Science Translational Medicine
|March 4, 2016
PubMed

Insights

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway show promise in cancer treatment. This study explores tumor microenvironment markers to predict and enhance responses to these therapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Immune checkpoint blockade targeting the PD-1/PD-L1 pathway offers durable antitumor responses in a subset of cancer patients.
  • Improving and predicting clinical responses to anti-PD therapy remains a critical challenge in cancer immunology.

Purpose of the Study:

  • To investigate the role of the tumor microenvironment in predicting and enhancing responses to PD-1/PD-L1 pathway blockade.
  • To evaluate potential therapeutic response markers within the tumor microenvironment.

Main Methods:

  • Analysis of PD-L1 and PD-1 expression patterns.
  • Assessment of genetic mutations, neoantigens, and cancer epigenetics.
  • Evaluation of the effector T cell landscape and microbiota composition.

Main Results:

  • Identification of key tumor microenvironment factors influencing anti-PD therapy response.
  • Clarification of mechanisms by which these markers shape and predict therapeutic outcomes.
  • Exploration of rational combination strategies with PD pathway blockade.

Conclusions:

  • Tumor microenvironment characteristics are crucial for predicting and optimizing anti-PD therapy efficacy.
  • Understanding these markers can guide personalized treatment strategies and combination therapies.
  • Further research into these markers holds potential for broader application of immunotherapy.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K